A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

NCT00549666 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics

Interventions

DRUG: Lurasidone 40 mg
DRUG: Placebo 40 mg
DRUG: Ortho Tri-Cyclen

Sponsor

Sumitomo Pharma America, Inc.